This site is intended for Healthcare professionals only.

USFDA approves Bristol-Myers Opdivo for bladder cancer


USFDA approves Bristol-Myers Opdivo for bladder cancer

The U.S. Food and Drug Administration expanded the use of Bristol-Myers Squibb Co’s Opdivo to include treatment of urothelial carcinoma, the most common type of bladder cancer.

Opdivo, part of a new class of medicines designed to use the body’s own immune system to fight cancer, is already approved to treat advanced melanoma, a form of lung cancer, kidney cancer, and Hodgkin lymphoma.

Investors were disappointed last month when Bristol-Myers said it would not seek accelerated FDA approval for a combination of Opdivo and another immunotherapy, Yervoy, as an initial treatment for lung cancer.

The FDA is slated to decide in May whether to approve rival Merck & Co Inc’s combination of immunotherapy Keytruda and chemotherapy for first-line lung cancer.



Source: Reuters
0 comment(s) on USFDA approves Bristol-Myers Opdivo for bladder cancer

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted